AU2002338431A1 - Sequence characteristics of bladder cancer - Google Patents

Sequence characteristics of bladder cancer

Info

Publication number
AU2002338431A1
AU2002338431A1 AU2002338431A AU2002338431A AU2002338431A1 AU 2002338431 A1 AU2002338431 A1 AU 2002338431A1 AU 2002338431 A AU2002338431 A AU 2002338431A AU 2002338431 A AU2002338431 A AU 2002338431A AU 2002338431 A1 AU2002338431 A1 AU 2002338431A1
Authority
AU
Australia
Prior art keywords
sequence characteristics
bladder cancer
bladder
cancer
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002338431A
Inventor
Elena Feinstein
Orna Mor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quark Pharmaceuticals Inc
Original Assignee
Quark Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/825,682 external-priority patent/US6998232B1/en
Application filed by Quark Biotech Inc filed Critical Quark Biotech Inc
Publication of AU2002338431A1 publication Critical patent/AU2002338431A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2002338431A 2001-04-04 2002-04-04 Sequence characteristics of bladder cancer Abandoned AU2002338431A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/825,682 2001-04-04
US09/825,682 US6998232B1 (en) 1999-09-27 2001-04-04 Methods of diagnosing bladder cancer
PCT/US2002/012774 WO2002086084A2 (en) 2001-04-04 2002-04-04 Sequence characteristics of bladder cancer

Publications (1)

Publication Number Publication Date
AU2002338431A1 true AU2002338431A1 (en) 2002-11-05

Family

ID=25244665

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002338431A Abandoned AU2002338431A1 (en) 2001-04-04 2002-04-04 Sequence characteristics of bladder cancer

Country Status (2)

Country Link
AU (1) AU2002338431A1 (en)
WO (1) WO2002086084A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
DE10309729A1 (en) * 2003-02-26 2004-09-16 Hinzmann, Bernd, Dr. Human nucleic acid sequences from bladder cancer
NZ595684A (en) * 2004-07-23 2013-06-28 Pacific Edge Biotechnology Ltd Urine markers for detection of bladder cancer
NZ545243A (en) 2006-02-10 2009-07-31 Pacific Edge Biotechnology Ltd Urine gene expression ratios for detection of cancer
PL2621526T3 (en) 2010-09-29 2018-11-30 Agensys, Inc. Antibody drug conjugates (adc) that bind to 191p4d12 proteins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0816851A3 (en) * 1991-01-15 2000-08-23 Oy Biotie Therapies Detection of syndecan content in body fluids for indication of malignant transformation of cells
WO1999014372A1 (en) * 1997-09-15 1999-03-25 Abbott Laboratories Reagents and methods useful for detecting diseases of the urinary tract
AU3316600A (en) * 1999-02-22 2000-09-21 Torben F. Orntoft Gene expression in bladder tumors
AU1492601A (en) * 1999-09-27 2001-04-30 Quark Biotech, Inc. Sequences characteristic of bladder cancer

Also Published As

Publication number Publication date
WO2002086084B1 (en) 2003-11-20
WO2002086084A2 (en) 2002-10-31
WO2002086084A3 (en) 2003-03-27

Similar Documents

Publication Publication Date Title
AU2002313559A1 (en) Genes
AU2002254570A1 (en) Epitope sequences
AUPR395801A0 (en) Antibodies against cancer
AU2002308154A1 (en) Triazolopyrimidines
AU2002349543A1 (en) Tumor antigens
AU2002226708A1 (en) Electric-wave absorber
AU2002357966A1 (en) Mobile fitness aid
AU2002335667A1 (en) Modified reoviral therapy
AU2002338431A1 (en) Sequence characteristics of bladder cancer
AU2002351382A1 (en) Combination cancer therapy
AU2002364322A1 (en) Handbag
AU2002359898A1 (en) Preparation of alpha-diimines
AU2002224498A1 (en) Webnotize transformation application
AUPR589001A0 (en) An antibody cancer therapeutic
AU2002302838A1 (en) Cancer associated protein
AU2002306319A1 (en) Tumor antigen
AU2002363198A1 (en) Tumor antigen
AU2002310189A1 (en) Tumor therapy
AUPR955901A0 (en) Inflatable brassiere
AU2002349647A1 (en) Tumor necrosis agent
AU2002341240A1 (en) An efficient synthesis of 5-heteroatom-containing-pyrazoles
AU2002357687A1 (en) Pyrazolopyrimidines
AUPR969801A0 (en) Therapeutic compounds - ii
AU2002226798A1 (en) Ask transceiver
AU2002304671A1 (en) Triazolopyrimidines

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase